Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response

Journal of Infection

Volumn 56, Issue 5, 2008, Pages 340-347

  Djoba Siawaya, Joel Fleury ^a   Bapela, Nchinya Bennedict ^a   Ronacher, Katharina ^a   Veenstra, Hanne ^a   Kidd, Martin ^b   Gie, Robert ^b   Beyers, Nulda ^b   van Helden, Paul ^a   Walzl, Gerhard ^a  

^a Department of Biomedical Sciences   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Anti tuberculosis treatment; Biomarkers; Immune parameters; Sputum culture; Tuberculosis

Indexed keywords

C REACTIVE PROTEIN; DEATH RECEPTOR 5; ETHAMBUTOL; GRANZYME B; INTERCELLULAR ADHESION MOLECULE 1; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UROKINASE RECEPTOR;

ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOLOGICAL PARAMETERS; LUNG ALVEOLUS; LUNG TUBERCULOSIS; MATHEMATICAL MODEL; MYCOBACTERIUM TUBERCULOSIS; PROTEIN BLOOD LEVEL; SEROLOGY; SHORT COURSE THERAPY; SPUTUM CULTURE; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CULTURE MEDIA; DRUG THERAPY, COMBINATION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 42749083261     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.02.007     Document Type: Article

References (48)

1. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Treatment of tuberculosis: recommendations and reports. Morbidity and Mortality Weekly Report 2003 Jun 20;52(RR-11):2.
2. Caminero Luna J.A. Tuberculosis guide for specialist physicians (2004), International Union Against Tuberculosis and Lung Disease, France p. 23
3. Jasmer R.M., Seaman C.B., Gonzalez L.C., Kawamura L.M., Osmond D.H., and Daley C.L. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med 170 5 (2004 Sep 1) 561-566
4. Schluger N.W., Harkin T., and Rom W. Principles of therapy of tuberculosis in the modern era. 1st ed. (1996), Little, Brown and Company, Boston, MA
5. Enarson D.E., Rieder H.L., Arnadottir T., and Trebucq A. Management of tuberculosis a guide for low income countries. 5th ed. (2000), IUATLD, France
6. Wallis R.S., Patil S., Cheon S.H., Edmonds K., Phillips M., Perkins M.D., et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43 11 (1999) 2600-2606
7. March F., Garriga X., Rodriguez P., Moreno C., Garrigo M., Coll P., et al. Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clin Infect Dis 25 5 (1997 Nov) 1044-1047
8. Deoskar R.B., Sengupta B., Rajan K.E., Barthwa S., Falleiro J., and Sharma S.K. Study of drug resistant pulmonary tuberculosis. MJAFI 61 (2005) 245-248
9. Demir T., Yalçinoz C., Keskinel I., Demiröz F., and Yildirim N. sICAM-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis 6 2 (2002 Feb) 155-159
10. Eugen-Olsen J., Gustafson P., Sidenius N., Fischer T.K., Parner J., Aaby P., et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 6 8 (2002) 686-692
11. Juffermans N.P., Verbon A., van Deventer S.J., van Deutekom H., Speelman P., and van der Poll T. Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis. Am J Respir Crit Care Med 157 4 (1998 Apr 1) 1328-1331
12. Lai C.K., Wong K.C., Chan C.H., Ho S.S., Chung S.Y., Haskard D.O., et al. Circulating adhesion molecules in tuberculosis. Clin Exp Immunol 94 3 (1993 Dec) 522-526
13. Lawn S.D., Rudolph D., Wiktor S., Oulibaly D., Ckah A., and Lal R.B. Tuberculosis (TB) and HIV infection are independently associated with elevated serum concentrations of tumour necrosis factor receptor type 1 and beta-2-microglobulin, respectively. Clin Exp Immunol 122 (2000) 79-84
14. Saltini C., and Colizzi V. Soluble immunological markers of disease activity in tuberculosis. Eur Respir J 14 3 (1999 Sep) 485
15. Cooper A.M., D'Souza C., Frank A.A., and Orme I.M. The course of Mycobacterium tuberculosis infection in the lungs of mice lacking expression of either perforin- or granzyme-mediated cytolytic mechanisms. Infect Immun 65 4 (1997 Apr 1) 1317-1320
16. Lienhardt C., Azzurri A., Amedei A., Fielding K., Sillah J., Sow O.Y., et al. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol 32 (2002) 1605-1613
17. Verver S., Warren R.M., Beyers N., Richardson M., van der Spuy G.D., Borgdorff M.W., et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 171 12 (2005 Jun 15) 1430-1435
18. + natural killer T cells in fast treatment responders. Clin Exp Immunol 145 2 (2006) 252-260
19. Lawson L., Yassin M.A., Ramsay A., Olajide I., Thacher T.D., Davies P.D.O., et al. Microbiological validation of smear microscopy after sputum digestion with bleach; a step closer to a one-stop diagnosis of pulmonary tuberculosis. Tuberculosis 86 1 (2006 Jan) 34-40
20. Simon G. Radiology in epidemiological studies and some therapeutic trials. Br Med J 2 5512 (1966) 491-494
21. Trevor H., Robert T., and Jerome F. The elements of statistical learning. Data mining, inference and prediction (2001), Springer-Verlag, New York, Berlin, Heidelberg
22. Wallis R.S. Surrogate markers to assess new therapies for drug-resistant tuberculosis. Expert Rev Anti Infect Ther 5 2 (2007 Apr) 163-168
23. Hellyer T.J., DesJardin L.E., Teixeira L., Perkins M.D., Cave M.D., and Eisenach K.D. Detection of viable Mycobacterium tuberculosis by reverse transcriptase-strand displacement amplification of mRNA. J Clin Microbiol 37 3 (1999 Mar 1) 518-523
24. Dheda K., Chang J.S., Breen R.A., Haddock J.A., Lipman M.C., Kim L.U., et al. Expression of a novel cytokine, IL-4delta2, in HIV and HIV-tuberculosis co-infection. AIDS 19 15 (2005) 1601-1606
25. Wallis R.S., Perkins M., Phillips M., Joloba M., Demchuk B., Namale A., et al. Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment. J Infect Dis 178 4 (1998) 1115-1121
26. de Beer F.C., Nel A.E., Gie R.P., Donald P.R., and Strachan A.F. Serum amyloid A protein and C-reactive protein levels in pulmonary tuberculosis: relationship to amyloidosis. Thorax 39 3 (1984) 196-200
27. Bajaj G., Rattan A., and Ahmad P. Prognostic value of 'C' reactive protein in tuberculosis. Indian Pediatr 26 10 (1989) 1010-1013
28. Nokta M., Rossero R., Loesch K., and Pollard R.B. Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea. AIDS Res Hum Retroviruses 13 18 (1997) 1633-1688
29. Brahmbhatt S., Black G.F., Carroll N.M., Beyers N., Salker F., Kidd M., et al. Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy. Clin Exp Immunol 146 2 (2006) 243-252
30. Plit M.L., Anderson R., van Rensburg C.E.J., Page-Shipp L., Blott J.A., Fresen J.L., et al. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J 12 (1998) 351-356
31. Mukae H., Ashitani J.I., Tokojima M., Ihi T., Kohno S., and Matsukura S. Elevated levels of circulating adhesion molecules in patients with active pulmonary tuberculosis. Respirology 8 3 (2003) 326-331
32. Shijubo N., Imai K., Nakanishi F., Yachi A., and Abe S. Elevated concentrations of circulating ICAM-1 in far advanced and miliary tuberculosis. Am Rev Respir Dis 148 5 (1993) 1298-1301
33. Chang K.C., Leung C.C., Yew W.W., Ho S.C., and Tam C.M. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 170 (2004) 1124-1130
34. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Am Rev Respir Dis 143 (1990) 700-706
35. Panjabi R., Comstock G.W., and Golub J.E. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 11 (2007 Aug) 828-837
36. Guler M., Unsal E., Dursun B., AydIn O., and Capan N. Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis. Int J Clin Pract 61 2 (2007) 231-235
37. Huang C.T., Workman C.J., Flies D., Pan X., Marson A.L., Zhou G., et al. Role of LAG-3 in regulatory T cells. Immunity 21 4 (2004 Oct) 503-513
38. Chan F.K.-M., Siegel R.M., and Lenardo M.J. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 13 4 (2000 Oct) 419-422
39. Hehlgans T., and Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115 1 (2005) 1-20
40. Jacobs M., Brown N., Allie N., Chetty K., and Ryffel B. Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity. Pathobiology 68 (2000) 68-75
41. Kim E.Y., Priatel J.J., Teh S.J., and Teh H.S. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 176 2 (2006) 1026-1035
42. hi T-regulatory cells. Blood 108 1 (2006 Jul 1) 253-261
43. Chan F.K., and Lenardo M.J. A crucial role for p80 TNF-R2 in amplifying p60 TNF-R1 apoptosis signals in T lymphocytes. Eur J Immunol 30 2 (2000) 652-660
44. Grell M., Zimmermann G., Gottfried E., Chen C.M., Grünwald U., Huang D.C., et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J 18 11 (1999) 3034-3043
45. Mori T., Doi R., Toyoda E., Koizumi M., Ito D., Kami K., et al. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery 138 1 (2005 Jul) 71-77
46. de Jong S., Timmer T., Heijenbrok F.J., and de Vries E.G. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev 20 1-2 (2001) 51-56
47. Corazza N., Brumatti G., Schaer C., Cima I., Wasem C., and Brunner T. TRAIL and immunity: more than a license to kill tumor cells. Cell Death Differ 11 Suppl. 2 (2004 Dec) S122-S125
48. The Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360 9332 (2002 Aug 17) 528-534